DR Reddy Slaboratories Inc Pharmaceutical Import Profile — United States (DGFT 2022–2026)

Name: DR Reddy Slaboratories Inc Pharmaceutical Import Records from India — 2 Products, $5.8M FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

DR Reddy Slaboratories Inc — Pharmaceutical Importer Profile (2026) | 2 Products, $5.8M Trade | TransData Nexus

DR Reddy Slaboratories Inc

Pharmaceutical Importer · United States · Analgesics & Antipyretics Focus · $5.8M Total Trade · DGFT Verified

DR Reddy Slaboratories Inc is a pharmaceutical importer based in United States with a total trade value of $5.8M across 2 products in 2 therapeutic categories. Based on 117 verified import shipments from Indian Customs (DGFT) records, the company actively imports across multiple product segments. DR Reddy Slaboratories Inc sources from 1 verified Indian supplier, with Dr Reddys Laboratories Limited accounting for 100.0% of imports.

DR Reddy Slaboratories Inc — Import Portfolio & Supplier Network

DR Reddy Slaboratories Inc import network — 2 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to DR Reddy Slaboratories Inc?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Dr Reddys Laboratories Limited	$17.5M	460	100.0%

DR Reddy Slaboratories Inc sources from 1 verified Indian supplier across 438 distinct formulations. The sourcing is highly concentrated — Dr Reddys Laboratories Limited accounts for 100.0% of total imports, indicating a strategic single-source relationship.

Formulation	Value	Ships
300036534 diclofenac sodium topical gel1% 100gmotc-cl-lami ndc code no:4359897710 anda	$188.1K	5
300036534 diclofenac sodium topical gel1% 100gmotc-cl-lami ndc code no:343598977102 anda	$150.0K	3
300036401 diclofenac gel 150g hca diclofenac sodium topical gel 1%lamindc codeno:4359888515 anda code: 210986 batch	$150.0K	3
300036534 diclofenac sodium topical gel1% 100gmotc-cl-lamindc code no:343598977102 anda	$125.5K	4
Valsartan tablets USP 320mg90's17542x 90s packs= 1578780	$100.0K	2
Memantine hydrochloride tablets USP 10mg500 s 17011 x 500 s packs = 8505500	$100.0K	2
Omeprazole delayed-release capsules usp40mg 30 s 115248 x 30 s packs =	$100.0K	2
300036401 diclofenac gel 150g hca diclofenac sodium topical gel 1%lamindc codeno:4359888515 anda code:210986 batch	$100.0K	2
Fluconazole tablets USP 150MG 46400 x12's = 556800	$97.3K	2
Esomeprazole magnesium delayed-release capsules USP 20 MG 90 s 16968 x 90 s packs = 1527120	$76.3K	2
Palonosetron hcl injection 0.25MG/5ML 0.05 MG/ML 1	$65.7K	2
300036401 diclofenac gel 150g hca diclofenac sodium topical gel 1%lamindc codeno:4359888515 anda code	$53.3K	2
Amlodipine and benazepril hcl capsules USP 5MG/40MG 100s Pack 13215 x 100s	$50.0K	1
Diclofenac sodium topical gel 1% 150GM	$50.0K	1
300015335 ziprasidone hydrochloride capsules 60MG 60s	$50.0K	1

Import Portfolio — Top 2 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Diclofenac	Analgesics & Antipyretics	$3.4M	67	0.9%	11
2	Metoprolol	Cardiovascular	$2.5M	50	0.3%	15

DR Reddy Slaboratories Inc imports 2 pharmaceutical products across 2 categories into United States totaling $5.8M.

DR Reddy Slaboratories Inc — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

DR Reddy Slaboratories Inc is a pharmaceutical importer and buyer based in the United States, specializing in the acquisition of finished pharmaceutical formulations from India. The company operates as a key player in the U.S. pharmaceutical distribution network, focusing on sourcing and importing generic medications to meet domestic healthcare needs. While specific details about its parent company are not publicly disclosed, DR Reddy Slaboratories Inc maintains a significant presence in the U.S. market, contributing to the availability of affordable generic drugs.

The company's operations are characterized by a strategic focus on importing finished pharmaceutical products, including tablets, capsules, syrups, and injections, rather than raw active pharmaceutical ingredients (APIs) or bulk drugs. This approach aligns with the broader industry trend of sourcing generic formulations from India, which is recognized as a major supplier of affordable therapeutics globally. India's pharmaceutical sector is often referred to as the "pharmacy to the world" due to its substantial contribution to the global supply of generic medications.

2Distribution Network

DR Reddy Slaboratories Inc's distribution network in the United States is designed to ensure efficient delivery of imported pharmaceutical products to various stakeholders, including wholesalers, healthcare providers, and pharmacies. While specific warehouse locations and logistics capabilities are not publicly detailed, the company's operations are likely supported by a network of distribution centers strategically located to facilitate timely and reliable delivery across the country. This infrastructure is essential for maintaining the integrity of the pharmaceutical supply chain and ensuring that imported medications reach their intended destinations without compromising quality or safety.

3Industry Role

In the U.S. pharmaceutical supply chain, DR Reddy Slaboratories Inc functions primarily as a pharmaceutical importer and buyer, sourcing finished pharmaceutical formulations from Indian manufacturers. By focusing on importing generic medications, the company plays a crucial role in enhancing the availability of affordable therapeutic options within the U.S. market. This role is particularly significant given the substantial portion of generic drugs consumed in the U.S. that originate from India, highlighting the importance of such importers in meeting domestic healthcare demands.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — DR Reddy Slaboratories Inc

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

DR Reddy Slaboratories Inc demonstrates a high level of sourcing concentration, with all its imported pharmaceutical products originating from a single supplier: DR REDDYS LABORATORIES LIMITED. This exclusive sourcing arrangement, amounting to $17.5 million over 460 shipments, indicates a strategic partnership that likely offers benefits such as favorable pricing, consistent product quality, and reliable supply chain logistics. However, this single-source dependency also introduces potential risks, including vulnerability to supply disruptions or changes in the supplier's operational status. The stability of this relationship is crucial for DR Reddy Slaboratories Inc's operations, and any significant issues with the supplier could impact the company's ability to meet market demand.

2Supply Chain Resilience

The resilience of DR Reddy Slaboratories Inc's supply chain is closely tied to the stability and reliability of its sole supplier, DR REDDYS LABORATORIES LIMITED. Given the exclusive nature of this sourcing arrangement, the company may face challenges in diversifying its supplier base, which could limit its ability to mitigate risks associated with supply chain disruptions. Additionally, the company's focus on importing finished pharmaceutical formulations from India means that any regulatory changes or logistical challenges affecting Indian exports could have a direct impact on DR Reddy Slaboratories Inc's operations. Ensuring compliance with U.S. Food and Drug Administration (FDA) regulations and maintaining robust quality control measures are essential for mitigating these risks and ensuring a resilient supply chain.

Importing Pharmaceuticals into United States — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for United States

1Regulatory Authority & Framework

In the United States, the Food and Drug Administration (FDA) serves as the primary regulatory authority overseeing the importation of pharmaceutical products. The FDA enforces the Federal Food, Drug, and Cosmetic Act (FD&C Act), which sets forth the legal framework for the importation, distribution, and marketing of drugs within the U.S. This legislation mandates that all drugs, including those imported from foreign countries, must be safe, effective, and manufactured in compliance with established quality standards. The FDA's role includes reviewing and approving drug applications, conducting inspections of manufacturing facilities, and ensuring that imported drugs meet the same standards as domestically produced products.

2Import Licensing & GMP

Import licensing requirements for pharmaceutical products entering the United States are governed by the FDA. Importers must ensure that their products comply with FDA regulations, including obtaining necessary approvals and certifications. Good Manufacturing Practice (GMP) certification is a critical component of this compliance. The FDA recognizes GMP certifications from various international bodies, including the European Union (EU), the World Health Organization (WHO), and the Pharmaceutical Inspection Co-operation Scheme (PIC/S). These certifications attest to the quality and safety of pharmaceutical products and are essential for importers to demonstrate compliance with FDA standards.

DR Reddy Slaboratories Inc — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

DR Reddy Slaboratories Inc's focus on importing pharmaceutical products in the analgesics and antipyretics, as well as cardiovascular therapeutic categories, aligns with significant market demand in the United States. Analgesics and antipyretics are widely used for pain relief and fever reduction, while cardiovascular medications are essential for managing heart-related conditions. The company's importation of these products suggests a strategic approach to meeting the healthcare needs of the U.S. population, particularly in areas with high prevalence of pain and cardiovascular diseases. By sourcing these medications from India, DR Reddy Slaboratories Inc contributes to the availability of affordable treatment options in the U.S. market.

2Sourcing Profile

DR Reddy Slaboratories Inc's sourcing strategy is characterized by a focus on generic drug formulations, primarily sourced from India. This approach leverages India's established reputation as a major supplier of affordable and high-quality generic pharmaceuticals. By importing finished formulations, the company ensures that the products are ready for distribution and use, streamlining the supply chain and reducing time to market. This strategy also allows DR Reddy Slaboratories Inc to offer a diverse range of therapeutic options to meet the varied needs of the U.S. healthcare system.

Market Positioning

Seller's Guide — How to Become a Supplier to DR Reddy Slaboratories Inc

Opportunity assessment, qualifications, and practical approach strategy

1Opportunity Assessment

There is a realistic opportunity for new Indian suppliers to engage with DR Reddy Slaboratories Inc, particularly in therapeutic categories where the company seeks to expand its product offerings. Identifying gaps in the current sourcing strategy, such as the need for additional formulations or alternative suppliers, could present avenues for collaboration. New suppliers would need to demonstrate compliance with FDA regulations, maintain high-quality manufacturing standards, and offer competitive pricing to meet the demands of the U.S.

TransData Nexus Research · Industry procurement practicesMar 2026

Frequently Asked Questions — DR Reddy Slaboratories Inc

What products does DR Reddy Slaboratories Inc import from India?

DR Reddy Slaboratories Inc imports 2 pharmaceutical products across 2 categories. Top imports: Diclofenac ($3.4M), Metoprolol ($2.5M).

Who supplies pharmaceuticals to DR Reddy Slaboratories Inc from India?

DR Reddy Slaboratories Inc sources from 1 verified Indian suppliers. The primary supplier is Dr Reddys Laboratories Limited (100.0% of imports, $17.5M).

What is DR Reddy Slaboratories Inc's total pharmaceutical import value?

DR Reddy Slaboratories Inc's total pharmaceutical import value from India is $5.8M, based on 117 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does DR Reddy Slaboratories Inc focus on?

DR Reddy Slaboratories Inc imports across 2 categories. The largest: Analgesics & Antipyretics (57.3%), Cardiovascular (42.7%).

Get Full DR Reddy Slaboratories Inc Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. For current shipment-level data, contact TransData Nexus.